Rapport Therapeutics (NASDAQ:RAPP) Stock Price Down 7.2% – Here’s What Happened

02 Jan 2026, 14:32 by Teresa Graham · The Cerbat Gem

Rapport Therapeutics, Inc. (NASDAQ:RAPP – Get Free Report)’s share price was down 7.2% on Friday . The company traded as low as $28.30 and last traded at $28.17. Approximately 169,236 shares changed hands during mid-day trading, a decline of 57% from the average daily volume of 394,998 shares. The stock had previously closed at $30.34.

Analysts Set New Price Targets

RAPP has been the topic of a number of analyst reports. Wall Street Zen upgraded Rapport Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, December 14th. HC Wainwright boosted their price objective on Rapport Therapeutics from $34.00 to $40.00 and gave the company a “buy” rating in a research report on Tuesday, December 9th. Citizens Jmp upped their target price on Rapport Therapeutics from $77.00 to $80.00 and gave the stock a “market outperform” rating in a research note on Friday, November 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Rapport Therapeutics in a research note on Wednesday, October 8th. Finally, Wells Fargo & Company set a $51.00 price objective on shares of Rapport Therapeutics in a research report on Friday, December 19th. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Rapport Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $48.33.

View Our Latest Report on Rapport Therapeutics

Rapport Therapeutics Stock Performance

The company has a market cap of $1.35 billion, a price-to-earnings ratio of -10.42 and a beta of 1.63. The firm’s 50 day simple moving average is $28.19 and its 200-day simple moving average is $21.92.

Rapport Therapeutics (NASDAQ:RAPP – Get Free Report) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.71) earnings per share for the quarter, topping the consensus estimate of ($0.77) by $0.06. As a group, sell-side analysts expect that Rapport Therapeutics, Inc. will post -3.65 EPS for the current fiscal year.

Insider Activity at Rapport Therapeutics

In related news, CEO Abraham Ceesay sold 5,083 shares of Rapport Therapeutics stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $29.63, for a total transaction of $150,609.29. Following the transaction, the chief executive officer owned 30,895 shares in the company, valued at approximately $915,418.85. This trade represents a 14.13% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider David Bredt sold 8,500 shares of the business’s stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $30.02, for a total transaction of $255,170.00. Following the transaction, the insider directly owned 392,642 shares in the company, valued at approximately $11,787,112.84. The trade was a 2.12% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 58,248 shares of company stock valued at $1,568,766. Insiders own 13.57% of the company’s stock.

Institutional Trading of Rapport Therapeutics

Hedge funds have recently made changes to their positions in the company. Strs Ohio increased its stake in Rapport Therapeutics by 23.5% during the third quarter. Strs Ohio now owns 2,100 shares of the company’s stock worth $62,000 after purchasing an additional 400 shares during the period. Creative Planning grew its holdings in shares of Rapport Therapeutics by 12.8% in the third quarter. Creative Planning now owns 11,959 shares of the company’s stock valued at $355,000 after purchasing an additional 1,357 shares in the last quarter. Russell Investments Group Ltd. purchased a new stake in Rapport Therapeutics during the 3rd quarter worth approximately $43,000. Two Sigma Investments LP lifted its holdings in Rapport Therapeutics by 8.9% during the 3rd quarter. Two Sigma Investments LP now owns 21,500 shares of the company’s stock worth $639,000 after buying an additional 1,757 shares in the last quarter. Finally, Acuta Capital Partners LLC boosted its position in Rapport Therapeutics by 22.0% in the 2nd quarter. Acuta Capital Partners LLC now owns 20,000 shares of the company’s stock valued at $227,000 after buying an additional 3,600 shares during the period.

Rapport Therapeutics Company Profile

(Get Free Report)

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.